PL432884A1 - Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu - Google Patents

Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu

Info

Publication number
PL432884A1
PL432884A1 PL432884A PL43288420A PL432884A1 PL 432884 A1 PL432884 A1 PL 432884A1 PL 432884 A PL432884 A PL 432884A PL 43288420 A PL43288420 A PL 43288420A PL 432884 A1 PL432884 A1 PL 432884A1
Authority
PL
Poland
Prior art keywords
rna
mrna
applications
synthesizing
end cap
Prior art date
Application number
PL432884A
Other languages
English (en)
Inventor
Marcin WARMIŃSKI
Paweł SIKORSKI
Joanna Kowalska
Jacek Jemielity
Original Assignee
Uniwersytet Warszawski
Explorna Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski, Explorna Therapeutics Spółka Z Ograniczoną Odpowiedzialnością filed Critical Uniwersytet Warszawski
Priority to PL432884A priority Critical patent/PL432884A1/pl
Priority to KR1020227030073A priority patent/KR20220163360A/ko
Priority to AU2021219237A priority patent/AU2021219237A1/en
Priority to PCT/PL2021/050006 priority patent/WO2021162566A1/en
Priority to JP2022548961A priority patent/JP2023513756A/ja
Priority to EP21754329.7A priority patent/EP4103578A4/en
Priority to CA3167563A priority patent/CA3167563A1/en
Priority to US17/798,102 priority patent/US20230295215A1/en
Publication of PL432884A1 publication Critical patent/PL432884A1/pl
Priority to JP2025162161A priority patent/JP2026012181A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Wynalazek dotyczy nowych analogów kapu końca 5' mRNA, cząsteczek RNA je zawierających, ich zastosowań i sposobów ich syntezy in vitro, jak również sposobu syntezy białka lub peptydu in vitro lub w hodowlach komórkowych, który to sposób obejmuje translację cząsteczki RNA.
PL432884A 2020-02-12 2020-02-12 Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu PL432884A1 (pl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PL432884A PL432884A1 (pl) 2020-02-12 2020-02-12 Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
KR1020227030073A KR20220163360A (ko) 2020-02-12 2021-02-12 포스페이트 잔기 내에서 변형된 신규 mRNA 5'-말단 캡 유사체, 이를 혼입한 RNA 분자, 이의 용도 및 RNA 분자 또는 펩티드의 합성 방법
AU2021219237A AU2021219237A1 (en) 2020-02-12 2021-02-12 Novel mRNA 5'-end cap analogs modified within phosphate residues, rna molecule incorporating the same, uses thereof and method of synthesizing RNA molecule or peptide
PCT/PL2021/050006 WO2021162566A1 (en) 2020-02-12 2021-02-12 Novel mrna 5'-end cap analogs modified within phosphate residues, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
JP2022548961A JP2023513756A (ja) 2020-02-12 2021-02-12 リン酸残基内で修飾された新規ｍＲＮＡ５’－末端キャップ類似体、それを組み込んだＲＮＡ分子、それらの使用、及びＲＮＡ分子又はペプチドを合成する方法
EP21754329.7A EP4103578A4 (en) 2020-02-12 2021-02-12 Novel mrna 5'-end cap analogs modified within phosphate residues, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
CA3167563A CA3167563A1 (en) 2020-02-12 2021-02-12 Novel mrna 5'-end cap analogs modified within phosphate residues, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
US17/798,102 US20230295215A1 (en) 2020-02-12 2021-02-12 Novel mrna 5'-end cap analogs modified within phosphate residues, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule or peptide
JP2025162161A JP2026012181A (ja) 2020-02-12 2025-09-29 リン酸残基内で修飾された新規ｍＲＮＡ５’－末端キャップ類似体、それを組み込んだＲＮＡ分子、それらの使用、及びＲＮＡ分子又はペプチドを合成する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL432884A PL432884A1 (pl) 2020-02-12 2020-02-12 Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu

Publications (1)

Publication Number Publication Date
PL432884A1 true PL432884A1 (pl) 2021-08-16

Family

ID=77291762

Family Applications (1)

Application Number Title Priority Date Filing Date
PL432884A PL432884A1 (pl) 2020-02-12 2020-02-12 Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu

Country Status (8)

Country Link
US (1) US20230295215A1 (pl)
EP (1) EP4103578A4 (pl)
JP (2) JP2023513756A (pl)
KR (1) KR20220163360A (pl)
AU (1) AU2021219237A1 (pl)
CA (1) CA3167563A1 (pl)
PL (1) PL432884A1 (pl)
WO (1) WO2021162566A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4104687T (lt) 2015-09-21 2024-02-26 Trilink Biotechnologies, Llc Kompozicijos ir būdai, skirti 5'-kepurę turinčių rnr sintetinimui
CN116368226A (zh) 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法
KR20240141277A (ko) * 2022-01-27 2024-09-26 트리링크 바이오테크놀로지스, 엘엘씨 트리뉴클레오티드 캡 유사체 및 그의 사용 방법
CN115260264B (zh) * 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用
CA3206012A1 (en) 2022-02-28 2023-08-28 Guangzhou Henovcom Bioscience Co., Ltd. Compounds for rna capping and uses thereof
WO2024044741A2 (en) * 2022-08-26 2024-02-29 Trilink Biotechnologies, Llc Efficient method for making highly purified 5'-capped oligonucleotides
IL319652A (en) * 2022-10-04 2025-05-01 BioNTech SE RNA structures and their uses
CN116375781B (zh) * 2023-03-24 2023-12-29 江苏申基生物科技有限公司 一种tna修饰的帽类似物及其制备方法和应用
EP4464713A1 (en) 2023-05-18 2024-11-20 Siec Badawcza Lukasiewicz - PORT Polski Osrodek Rozwoju Technologii Circular rna analogs, preparation and application thereof
WO2025147660A2 (en) 2024-01-04 2025-07-10 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
CN117567528B (zh) * 2024-01-15 2024-04-05 天津全和诚科技有限责任公司 帽类似物及其合成方法和mRNA
WO2026010855A1 (en) 2024-07-02 2026-01-08 Trilink Biotechnologies, Llc Modified rna for increasing protein expression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1421189A2 (en) * 2001-08-22 2004-05-26 Helix Biopharma Corp. Method and device for integrated protein expression, purification and detection
PL215513B1 (pl) * 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
BR112017026543A2 (pt) * 2015-08-26 2018-08-14 Bison Therapeutics Inc plataforma de anticorpo multiespecífico e métodos relacionados
LT4104687T (lt) * 2015-09-21 2024-02-26 Trilink Biotechnologies, Llc Kompozicijos ir būdai, skirti 5'-kepurę turinčių rnr sintetinimui
WO2017066797A1 (en) * 2015-10-16 2017-04-20 Modernatx, Inc. Trinucleotide mrna cap analogs
PL415967A1 (pl) * 2016-01-29 2017-07-31 Univ Warszawski 5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
MX2020010871A (es) * 2018-03-15 2020-11-09 BioNTech SE Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
PL248416B1 (pl) 2020-02-12 2025-12-08 Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
CN116368226A (zh) 2020-09-04 2023-06-30 维乎医疗有限公司 用于加帽rna的组合物和方法

Also Published As

Publication number Publication date
KR20220163360A (ko) 2022-12-09
WO2021162566A1 (en) 2021-08-19
EP4103578A4 (en) 2024-01-10
JP2026012181A (ja) 2026-01-23
CA3167563A1 (en) 2021-08-19
AU2021219237A1 (en) 2022-09-08
JP2023513756A (ja) 2023-04-03
US20230295215A1 (en) 2023-09-21
EP4103578A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
PL432884A1 (pl) Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
PL432883A1 (pl) Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu
CL2021002742A1 (es) Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de francisella tularensis; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
BR112021025359A2 (pt) Composições de proteína anti-vegf e métodos para a produção das mesmas
PL417980A1 (pl) Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
PE20090483A1 (es) Vectores para la expresion multiple de genes
EP1871426A4 (en) RNA MOLECULES WITH LOW ACTIVATION
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
MX2022015376A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
JPWO2013118878A1 (ja) 環状ｒｎａ及びタンパク質の製造方法
MX2023001083A (es) Construcciones anti grupo de diferenciacion 93 (cd93) y usos de las mismas.
CY1120078T1 (el) Διαδικασια παραγωγης και επεξεργασιας του παραγοντα viii και τα παραγωγα του
RU2015119400A (ru) Средства и методы ферментативного получения l-метионина из о-фосфо-l-гомосерина и метантиола
EA202091349A1 (ru) Способы культивирования клеток
BRPI0410562B8 (pt) proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
BR112023026176A2 (pt) Vetores de expressão, vetores livres de sequência bacteriana e métodos de fabricação e uso dos mesmos
MX2022010985A (es) Expresión de proteínas sars-cov, constructos de ácido nucleico, proteínas tipo virus (vlp) y métodos relevantes a los mismos.
FI20115310L (fi) Proteaasientsyymi ja sen käytöt
ECSP077240A (es) Variantes mejoradas de la aprotinina
BR0213779A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
EA200800253A1 (ru) Бессывороточная культуральная среда для получения рекомбинантных гонадотропинов
BR0313083A (pt) moléculas de adamts4 modificadas,polinucleotìdeo, vetor, processos para produção, composição farmacêutica, bem como uso das mesmas
MX2022001211A (es) Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso.
MX2022001210A (es) Moléculas de complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso.